MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
0.9931
-0.0169
-1.67%
After Hours: 0.9997 +0.0066 +0.66% 19:16 12/26 EST
OPEN
1.000
PREV CLOSE
1.010
HIGH
1.019
LOW
0.9801
VOLUME
351.52K
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.7709
MARKET CAP
99.31M
P/E (TTM)
-3.2862
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDL last week (1215-1219)?
Weekly Report · 5d ago
First Berlin Equity Research Sets Cardiol Therapeutics Price Target at $7.80
Reuters · 12/17 13:38
Weekly Report: what happened at CRDL last week (1208-1212)?
Weekly Report · 12/15 10:14
Weekly Report: what happened at CRDL last week (1201-1205)?
Weekly Report · 12/08 10:13
Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/02 12:11
Canaccord Genuity Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)
TipRanks · 12/02 11:57
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 12/01 18:07
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
TipRanks · 12/01 16:55
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.